Cigalah Medpharm

What Cigalah Medpharm does

Cigalah Medpharm Trading LLC is a Dubai-headquartered (Barsha Heights) pharmaceutical distribution and commercialization company founded in 2007, operating three divisions — Aesthetics, Pharmaceuticals, and Retail Healthcare — across the GCC and broader MENA region. The company functions as a regional gateway for international healthcare brands, providing market entry, regulatory navigation, and distribution services to principals seeking Middle Eastern exposure. Its portfolio spans dermatology and wound care (Bella Aurora, Repigment12, KELO.CELL, CURAderm, Abilar), medical aesthetics (PBSerum recombinant enzymes, Hanheal exosomes, Novacutan BioPRO, Evolutha FHA injectables, Viderage), ophthalmology (VISMED, OptoClean), OBGYN (Cumlaude Lab, Mixaferrum Forte), pain management (Apotelmax), consumer healthcare (Probiolyte, CIGAFAST), genitourinary (Anantra), and anti-infective categories.

The business model is primarily transaction-fee distribution to hospitals, pharmacies, and aesthetic clinics, supplemented by licensing and royalty revenue from exclusive technology transfer agreements. The company's most significant commercial milestone is a $208.5 million exclusive agreement with South Korea's Astrogen signed in January 2026, covering supply ($131 million), regulatory milestone ($77.5 million on Korean approval), and double-digit royalties for autism treatment candidate AST-001 across 16 MENA countries. Cigalah Medpharm does not manufacture products; its competitive position is built on exclusive distribution rights for differentiated, often patent-protected brands and on regulatory/commercialization expertise in regional markets.

Name

Cigalah Medpharm

Legal name

Cigalah Medpharm Trading LLC

Website

https://cigalahmedpharm.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Cigalah Medpharm is a UAE-based pharmaceutical distribution and commercialization partner that serves as a regional gateway for international healthcare brands across aesthetics, pharma, and retail health in the GCC and MENA markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Aesthetics Distribution

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Health and Personal Care Retailers (456)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Pharmaceutical distribution
• Medical aesthetics distribution
• MENA healthcare commercialization
• Retail healthcare products
• Pharmaceutical licensing

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Distribution: Distribution of pharmaceutical products across multiple therapeutic categories including OBGYN, dermatology, ophthalmology, pain management, anti-infective, CNS, and genitourinary. Products are distributed to healthcare professionals and facilities across the GCC/MENA region.
2. Aesthetics Products Distribution: Distribution of medical aesthetics products including injectables, skincare, and aesthetic treatments. Products are distributed through professional healthcare channels targeting aesthetic clinics and practitioners.
3. Technology Transfer and Licensing: Revenue from technology transfer agreements and licensing deals for pharmaceutical products, such as the Astrogen $208.5 million deal including $131 million for supply and $77.5 million upon regulatory approval plus royalties.
4. Consumer Healthcare Products: Retail distribution of consumer healthcare solutions including Probiolyte, CIGAFAST, and other over-the-counter products through retail channels.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Cigalah Medpharm is a UAE-based distributor and commercialization partner that brings international pharmaceutical, medical aesthetics, and retail healthcare brands into the GCC and MENA markets. It operates three divisions — Aesthetics, Pharmaceuticals, and Retail Healthcare — distributing brands such as PBSerum, Hanheal, Novacutan BioPRO, Evolutha, Bella Aurora, Repigment12, VISMED, CIGAFAST, and Cumlaude Lab through professional healthcare and retail channels. The company also secures exclusive licensing and technology-transfer agreements, exemplified by a $208.5 million deal with Astrogen for autism treatment AST-001 across 16 MENA countries.

Product overview

Cigalah Medpharm is a UAE-based healthcare distributor operating across three divisions: Aesthetics, Pharmaceuticals, and Retail Healthcare. The company serves as a distribution and commercialization partner for international brands in the Middle East and North Africa region. In Aesthetics, the portfolio includes PBSERUM (recombinant enzymatic systems), Hanheal (exosome-based anti-aging), Novacutan BioPRO (hyaluronic acid biomodulators), Evolutha (injectable lifting solutions), and Viderage. The Pharmaceuticals division covers OBGYN, Dermatology and Wound Care, Ophthalmology, Pain Management, Anti-Infective, CNS, Genitourinary, and Consumer Solutions categories with products such as Apotelmax, VISMED, Repigment12, Bella Aurora, KELO.CELL, CURAderm, Abilar, Probiolyte, CIGAFAST, Anantra, Cumlaude Lab, and Mixaferrum Forte. The company also recently secured a $208.5 million partnership with Astrogen for autism treatment candidate AST-001 distribution across 16 MENA countries. Cigalah Medpharm functions as a regional gateway for brands seeking to enter the Middle Eastern market rather than manufacturing products.

Differentiator

Problem solved

Functional benefit

Brands

• PBSerum: The only brand worldwide with a unique range of 5 proprietary enzymes obtained through advanced technology. Products include Collagenases PB220, Lipase PB500, Lyase PB72K, Hyaluronidase PB3000, and Keratinase PB333.
• Hanheal
• Novacutan
• Evolutha
• Viderage

Products and services

• PBSerum Range of 5 proprietary recombinant enzymes (Collagenases, Lipase, Lyase, Hyaluronidase, Keratinase) used by aesthetic practitioners for facial and body enzymatic treatments, including HA (Low, Medium, High formulations), Specific triple-enzyme system, and HA Corrector.
• Hanheal Exosome-based aesthetics brand using ultrasound-directed permeation technology to deliver reprogramming factors derived from human dermal fibroblasts for cellular rejuvenation and anti-aging in face and hair.
• Novacutan BioPRO Matrix biomodulator developed through multiphase hyaluronic acid cross-linking with a three-level mechanism (extracellular, intracellular, subcellular/mitochondrial) for anti-inflammatory tissue activation.
• Evolutha Injectable lifting solution developed by Caromed Italia using Fragmented Hyaluronic Acid (FHA), choline, and amino acids that stimulates fibroblasts and collagen production without toxins.
• Viderage Aesthetic skincare brand.
• Bella Aurora Skincare brand with 130-year research history featuring B-CORE 221 targeted-delivery encapsulation to melanin-producing cells; portfolio spans dark spot treatment, anti-aging, sun protection, and cleansing.
• Repigment12 Patented vitiligo cream with a custom-designed 12-amino-acid peptide sequence that restores skin color by addressing chronic melanocyte detachment.
• KELO.CELL Silicone scar treatment gel combined with bioactive factors from totipotent stem cells for prevention and improvement of atrophic, hypertrophic, and keloid scars, contractures, stretch marks, and burns.
• CURAderm Powder spray for topical wound healing supporting physiological healing of cuts, abrasions, second-degree burns, and ulcers; key ingredients include Sodium Hyaluronate, Silver, and Light Kaolin.
• Abilar Resin salve ointment extracted from Picea abies that creates a protective barrier against bacteria and fungi, reducing wound irritation and pain for surgical, pressure ulcer, and chronic wound healing.
• VISMED Hyaluronic acid-based eye drops for dry eye treatment with an adaptable concentration range and well-tolerated formulation with over 15 years of clinical experience.
• OptoClean Eyecare range including eyelid towels, eye cleanser, and eye wash drops for daily protection against screen time, atmospheric factors, and contact lens use.
• Apotelmax Intravenous Paracetamol analgesic-antipyretic supplied in non-PVC bags with aluminum overwrap suitable for variable temperature geographies.
• Probiolyte Pioneering electrolyte-probiotic-prebiotic formulation with banana powder for restoration of fluids and gastrointestinal flora in dehydration from diarrhea, fever, or sports; available in adult and pediatric formulations.
• CIGAFAST Patented ORMICAP blend (L-Cystine, Biotin, Zinc, Niacin) for hair loss treatment and regrowth improvement targeting hair strength, scalp circulation, active hair bulbs, and amino acid metabolism.
• Cumlaude Lab Gynecologist-developed intimate care solutions for all life stages including childhood, pregnancy, breastfeeding, postpartum, and climacteric period.
• Mixaferrum Forte Iron deficiency treatment with an innovative bi-layer granular formulation using modified starch, phosphatidylcholine (PC), and phosphatidylserine (PS) for enhanced gastroresistance and intestinal absorption.
• Anantra 100% natural tablet supplement for sexual dysfunction combining herbal stimulants, vitamins, trace elements, and amino acids; available in male and female formulations.

Quantifiable outcome

• $208.5 million deal value with Astrogen for autism treatment commercialization across 16 MENA countries
• +1 more outcomes

Named customers1 record

Segments8 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• AstrogenflagshipStrategic or Co-development Partner · 7 January 2026UAE-based Cigalah Medpharm Trading LLC signed a $208.5 million exclusive agreement with South Korean clinical-stage pharmaceutical company Astrogen to transfer technology for autism spectrum disorder (ASD) treatment candidate AST-001 and commercialize it across 16 Middle East and North Africa countries. Astrogen will supply AST-001 worth $131 million and receive an additional $77.5 million upon Korean regulatory approval, plus double-digit royalties on future sales.
• PBSerumcoreChannel Partner/ Reseller/ DistributorDistribution partnership for PBSerum aesthetics products including the only brand worldwide with proprietary recombinant enzymes (Collagenases, Lipase, Lyase, Hyaluronidase, Keratinase) for facial and body treatments.
• HanhealcoreChannel Partner/ Reseller/ DistributorDistribution partnership for Hanheal exosome-based aesthetic products featuring exclusive ultrasound directed permeation technology that induces reprogramming factors to exosomes derived from human dermal fibroblasts.
• NovacutancoreChannel Partner/ Reseller/ DistributorDistribution partnership for Novacutan BioPRO Matrix Biomodulator featuring multiphase hyaluronic acid cross-linking technology with three levels of mechanism: Extracellular, Intracellular, and Subcellular/Mitochondrial.
• Caromed Italia (Evolutha)coreChannel Partner/ Reseller/ DistributorDistribution partnership for Evolutha injectable lifting solution developed by Caromed Italia, an innovative product providing Mesobotox therapy benefits without toxins using Fragmented Hyaluronic Acid, choline, and amino acids.
• Bella AuroracoreChannel Partner/ Reseller/ DistributorDistribution partnership for Bella Aurora skincare products featuring 130 years of skin research and B-CORE 221 technology for targeted delivery of encapsulated ingredients to melanin-producing cells.
• Matteo BordignonminorStrategic or Co-development PartnerResearch collaboration with Italian researcher Matteo Bordignon, MD, PhD, whose discoveries regarding chronic melanocyte detachment form the basis of the patented Repigment12 vitiligo treatment.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer and distributor serving the MENA region across branded generics, consumer healthcare, and aesthetics. Comparable in regional base, therapeutic breadth, and GCC distribution reach.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Leading Saudi-based pharmaceutical manufacturer and distributor with MENA-wide reach across multiple therapeutic categories including dermatology, OBGYN, and consumer health. Closely comparable in regional distribution model and product portfolio breadth.
• Tabuk Pharmaceuticals: Saudi-headquartered pharmaceutical company with branded generics, biologics, and consumer health portfolios distributed across MENA. Comparable therapeutic-area breadth and regional distribution footprint.

Regional players

• Dawaa & Al-Dawaa Medical Supplies Company: Largest pharmaceutical retail and distribution chain in Saudi Arabia with growing UAE/GCC presence. Comparable as a regional pharma distribution and retail platform serving the MENA consumer and professional healthcare markets.
• Nahdi Medical Company: Saudi-based retail pharmacy chain with expanding GCC footprint, distributing consumer healthcare and pharmaceutical products. Comparable on the consumer healthcare distribution and retail side of Cigalah's business.

Broad incumbents

• Galderma: Global dermatology and aesthetics major with strong MENA presence through distribution partners. Comparable on the medical aesthetics and dermatology side where Cigalah distributes brands like Bella Aurora and PBSerum.
• Sinclair Pharma (Croma-Pharma / Sinclair International): European aesthetics company with global distribution of injectable HA, botulinum toxin alternatives, and skincare. Comparable aesthetics product portfolio (e.g., Evolutha-like injectable lifting solutions) and channel structure through regional distributors.
• Alliance Healthcare (Walgreens Boots Alliance): Global pharmaceutical wholesaler and distributor with operations in multiple regions. Comparable as a wholesale distribution and commercialization partner for international pharma brands entering regional markets.
• Phoenix Group: European pharmaceutical distribution group with growing presence in MENA through partnerships. Comparable business model of cross-border pharma distribution and commercialization for international brand owners.
• Astellas Pharma MENA: Global pharmaceutical company with established MENA regional operations across specialty therapeutics. Comparable in leveraging regional distribution partners and licensing arrangements to commercialize branded pharmaceuticals across MENA markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/cigalahmedpharm.official
• Facebookfacebook.com/cigalahmedpharm.official
• LinkedInlinkedin.com/company/cigalahmedpharm

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cigalah Medpharm